Current Research & Development

When the next big advance happens in critical care, we plan to be there

Critical care has many significant needs. We are advancing research to meet those needs, as evidenced by

  • A rich late-stage pipeline focusing on promising compounds in critical care
  • 4,000 ICU patients studied around the world1

INOMAX® (nitric oxide) for inhalation


We are actively searching for new uses for INOMAX in special patient populations and are conducting studies that address interesting scientific questions and unmet medical needs for critical care patients.

Lucassin® (terlipressin)


Hepatorenal syndrome, or HRS Type 1, is a rare and often fatal condition of advancing kidney failure in patients with cirrhosis or other severe liver diseases. In many of these patients, a successful liver transplant is their only hope to reverse HRS Type I and restore normal kidney function.

Delivery systems


Ikaria’s hands-on understanding of the critical care environment helps us design at an optimum level. Beyond providing novel biotherapeutics, Ikaria also has expertise in developing drug-delivery systems.